Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| MRNA | Moderna, Inc. | -2.82% | 72.01 | 0.0% | $2372.81m | |
| NVAX | Novavax, Inc. | 4.83% | 178.51 | 251.8% | $1337.92m | |
| SRNE | Sorrento Therapeutics, Inc. | 30.51% | 18.82 | 1.5% | $899.58m | |
| GILD | Gilead Sciences, Inc. | -1.21% | 68.51 | 1.0% | $564.29m | |
| AMGN | Amgen, Inc. | -1.05% | 238.17 | 1.3% | $477.09m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -1.93% | 608.24 | 2.7% | $403.31m | |
| BNTX | BioNTech SE | -3.96% | 73.95 | 0.0% | $397.67m | |
| VRTX | Vertex Pharmaceuticals, Inc. | -1.56% | 268.73 | 1.9% | $369.46m | |
| BIIB | Biogen, Inc. | -1.78% | 300.26 | 1.6% | $363.67m | |
| ILMN | Illumina, Inc. | -0.65% | 353.35 | 3.5% | $342.14m | |
| VXRT | Vaxart, Inc. | 2.23% | 9.40 | 0.0% | $296.32m | |
| EBS | Emergent BioSolutions, Inc. | -0.19% | 130.41 | 6.4% | $188.70m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -1.36% | 101.88 | 2.0% | $166.53m | |
| IBIO | iBio, Inc. | -3.16% | 3.68 | 0.2% | $166.50m | |
| SGEN | Seattle Genetics, Inc. | -1.71% | 157.70 | 6.2% | $160.68m |
Company Profile
Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of cancer treatments. Its marketed product Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is offered for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.